Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis.

[1]  A. Fischer,et al.  Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study , 2014, The Lancet.

[2]  C. von Kalle,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.

[3]  Luca Biasco,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome , 2013, Science.

[4]  M. Grez,et al.  Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy. , 2013, Human gene therapy methods.

[5]  C. von Kalle,et al.  Preclinical Safety and Efficacy of Human CD34+ Cells Transduced With Lentiviral Vector for the Treatment of Wiskott-Aldrich Syndrome , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  Gary D Bader,et al.  Attenuation of miR-126 Activity Expands HSC In Vivo without Exhaustion , 2012, Cell stem cell.

[7]  L. Naldini,et al.  Exploiting microRNA regulation for genetic engineering. , 2012, Tissue antigens.

[8]  M. Cavazzana‐Calvo,et al.  Gene therapy for primary immunodeficiencies: Part 2. , 2012, Current opinion in immunology.

[9]  M. Grez,et al.  Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter , 2011, Gene Therapy.

[10]  D. Cesana,et al.  Genotoxicity assay for gene therapy vectors in tumor prone Cdkn2a⁻/⁻ mice. , 2012, Methods in enzymology.

[11]  R. Krance,et al.  Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. , 2012, The Journal of allergy and clinical immunology.

[12]  Chuanfeng Wu,et al.  Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity , 2011, Frontiers of medicine.

[13]  E. Laurenti,et al.  Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease , 2011, Gene Therapy.

[14]  Mamoru Ito,et al.  Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells. , 2011, Blood.

[15]  M. Washburn,et al.  Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein , 2011, Nature.

[16]  Andrea Cimarelli,et al.  A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1–derived lentiviral vectors , 2011, Nature Protocols.

[17]  L. Naldini.  Ex vivo gene transfer and correction for cell-based therapies , 2011, Nature Reviews Genetics.

[18]  C. von Kalle,et al.  Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  M. Dinauer,et al.  Gene therapy of chronic granulomatous disease: the engraftment dilemma. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  Kathryn L. Parsley,et al.  Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  Alessandra Biffi,et al.  Identification of Hematopoietic Stem Cell–Specific miRNAs Enables Gene Therapy of Globoid Cell Leukodystrophy , 2010, Science Translational Medicine.

[22]  Seger Ra.  Chronic granulomatous disease: recent advances in pathophysiology and treatment. , 2010, The Netherlands journal of medicine.

[23]  A. Thrasher,et al.  A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  A. Fischer,et al.  Immune deficiencies , infection , and systemic immune disorders Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe : Entering a new century , do we do better ? , 2010 .

[25]  H. Lodish,et al.  Alteration of processing induced by a single nucleotide polymorphism in pri-miR-126. , 2010, Biochemical and biophysical research communications.

[26]  Hans Martin,et al.  Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease , 2010, Nature Medicine.

[27]  D. Kuhns,et al.  Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. , 2010, Blood.

[28]  S. Holland,et al.  Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update). , 2000, Blood cells, molecules & diseases.

[29]  R. Seger.  Chronic granulomatous disease: recent advances in pathophysiology and treatment. , 2010, The Netherlands journal of medicine.

[30]  A. Towbin,et al.  Chronic granulomatous disease , 2010, Pediatric Radiology.

[31]  Zhixiong Li,et al.  Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  V. Arruda,et al.  Strategies to modulate immune responses: a new frontier for gene therapy. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  A. Plebani,et al.  Molecular characterization of a large cohort of patients with Chronic Granulomatous Disease and identification of novel CYBB mutations: an Italian multicenter study. , 2009, Molecular immunology.

[34]  A. Schambach,et al.  Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells , 2009, Gene Therapy.

[35]  Luigi Naldini,et al.  Stable knockdown of microRNA in vivo by lentiviral vectors , 2009, Nature Methods.

[36]  T. Golub,et al.  Distinct microRNA expression profiles in acute myeloid leukemia with common translocations , 2008, Proceedings of the National Academy of Sciences.

[37]  John McAnally,et al.  The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. , 2008, Developmental cell.

[38]  R. Seger.  Modern management of chronic granulomatous disease , 2008, British journal of haematology.

[39]  Luigi Naldini,et al.  Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state , 2007, Nature Biotechnology.

[40]  K. Krause,et al.  The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. , 2007, Physiological reviews.

[41]  Christof von Kalle,et al.  and insertional genotoxicity Cell culture assays reveal the importance of retroviral vector design for , 2006 .

[42]  A. J. Valente,et al.  Development of a synthetic promoter for macrophage gene therapy. , 2006, Human gene therapy.

[43]  L. Naldini,et al.  Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer , 2006, Nature Medicine.

[44]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[45]  B. Zweiman,et al.  Neutrophils , 2019, Nursing Critical Care.

[46]  L. Naldini,et al.  HIV-based vectors. Preparation and use. , 2002, Methods in molecular medicine.

[47]  M. Dinauer,et al.  Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease. , 1997, Blood.

[48]  J. Curnutte,et al.  Kinetic microplate assay for superoxide production by neutrophils and other phagocytic cells. , 1990, Methods in enzymology.